Study Information
Study Details
View study details on clinicaltrials.gov.
Locations
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
Phase II study of niraparib in patients with advanced melanoma with genetic homologous recombination (HR) mutation / alteration
Location: CPMC (San Francisco)
Please contact ClinicalResearch@sutterhealth.org for more details about study Tesaro IIP Kim
Eligibility Requirements
Patients with advanced melanoma with genetic homologous recombination (HR) mutation/ alteration including:
mutation/ deletion in ARID1A/B, ARID2, ATM, ATR, BARD1, BRCA1/2, BAP1, BRIP1, CHEK2, FANCD2, MRN11A, RAD50, RAD51, RAD54B (and/or other mutations deemed by the study team to be HR deficient); the genetic analysis for somatic mutations must be performed in a lab that has obtained CLIA certification.